Aptevo Therapeutics Reports First Quarter 2018 Financial Results

- May 10th, 2018

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and reported its financial results for the first quarter ended March 31, 2018. As quoted in the press release: “Turning to our ADAPTIR platform, enrollment is progressing in our otlertuzumab Phase 2 clinical study in peripheral … Continued

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and reported its financial results for the first quarter ended March 31, 2018.

As quoted in the press release:

“Turning to our ADAPTIR platform, enrollment is progressing in our otlertuzumab Phase 2 clinical study in peripheral T-cell lymphoma and our APVO414 Phase 1 clinical study in metastatic castration resistant prostate cancer. We anticipate reporting preliminary top-line data from each of these programs at the end of the year. We also recently announced an IND filing for APVO436, and anticipate moving this program into the clinic in the fourth quarter of 2018.  New preclinical data for APVO436 were presented at this year’s AACR annual meeting and were very favorably received by the medical and financial communities. The data, comparing APVO436 to an Aptevo-generated version of a competitor molecule, showed reduced cytokine release, positioning APVO436 potentially as a best-in-class molecule in the CD123 field.  Finally, we are on track to file a second IND in the fourth quarter of 2018 for our autoimmune bispecific candidate, APVO210, and anticipate this molecule will enter the clinic next year.  We believe the unique mechanism of action of APVO210, which retains the immunosuppressive function of IL-10 without inducing immuno-stimulation demonstrated in preclinical studies, positions this molecule very competitively in the autoimmune therapeutic field,” said Mr. White.

Click here to read the full press release.

 

New FREE Report: Investing in Psychedelics

   
What’s ahead for this exciting new segment? Learn more with our exclusive psychedelics report today. Published July 6, 2020.
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply